
Sacituzumab Tirumotecan Improves OS in 3L+ Gastroesophageal Cancer
Key Takeaways
- TroFuse-015 randomized 473 patients after ≥2 prior systemic lines to sac-TMT 4 mg/kg on days 1/15/29 every 6 weeks versus physician’s choice chemotherapy.
- Overall survival improved significantly with sac-TMT, and the effect was consistent across subgroups regardless of tumor TROP2 expression status.
Sac-TMT improved OS vs physician’s choice in pretreated gastroesophageal adenocarcinoma in the phase 3 TroFuse-015 trial; PFS was not improved.
The investigational TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) significantly improved overall survival (OS) compared with treatment of physician’s choice (TPC) in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least 2 prior lines of systemic therapy.1
At the final analysis of the phase 3 TroFuse-015 trial (NCT06356311), the OS benefit was statistically significant and was consistent across subgroups irrespective of tumor TROP2 expression. However, sac-TMT did not significantly improve progression-free survival (PFS) by blinded independent central review, a secondary end point.1
“There is a tremendous unmet need for therapies that can improve survival for these patients,” Marjorie Green, MD, senior vice president and head of oncology, global clinical development for Merck Research Laboratories, stated in a news release.
Treatment options for patients with gastroesophageal adenocarcinoma after 2 or more prior lines are limited, and the comparator regimens in TroFuse-015 were all single-agent chemotherapy, so an OS gain with a TROP2-directed ADC, if borne out in the full data, would add a new mechanism of action to this setting.
TroFuse-015 Trial Design
TroFuse-015 is a global, randomized, open-label, multicenter phase 3 trial that enrolled 473 patients with gastric, gastroesophageal junction, or esophageal adenocarcinoma after 2 or more prior lines of systemic therapy. Patients were randomly assigned to sac-TMT 4 mg/kg on days 1, 15, and 29 of each 6-week cycle or to TPC.
TPC options were:
- Trifluridine/tipiracil (Lonsurf) 35 mg/m² orally twice daily on days 1 to 5 and 8 to 12 of a 4-week cycle
- Irinotecan 150 mg/m² on days 1 and 15 of a 4-week cycle
- Paclitaxel 80 mg/m² on days 1, 8, and 15 of a 4-week cycle
- Docetaxel 75 mg/m² every 3 weeks.
OS is the primary end point, and secondary end points include PFS, objective response rate (ORR), and duration of response.
Sac-TMT Secondary End Points and Safety
The ORR numerically favored sac-TMT, but this end point was not formally tested under the prespecified statistical analysis plan. Merck stated that the safety profile was consistent with previous studies of sac-TMT and that no new safety signals emerged.
Merck plans to present the full data at a future medical meeting and to submit them to regulators.
Sac-TMT Development Across Solid Tumors
Sac-TMT carries a topoisomerase I inhibitor payload derived from belotecan, attached by a bifunctional linker. The agent
In May 2026, Merck reported that sac-TMT
“The data really is very robust in terms of showing that this is a new effective standard in this treatment setting,” said
“We look forward to discussing these data with regulatory authorities and sharing with the scientific community on behalf of patients who may benefit,” Green stated in the news release.1
REFERENCES
1. Merck announces TroFuse-015 trial evaluating sacituzumab tirumotecan (Sac-TMT) met primary endpoint of overall survival (OS) in third-line or later locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. News release. Merck. November 20, 2026. Accessed November 20, 2026. https://tinyurl.com/3k5ejhvx
2. Lorusso D, Martin-Babau J, Backes F, et al. Sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer: results from the phase 3 TroFuse-005/ENGOT-en23/GOG-3095 study. Presented at: 2026 ESMO Congress; October 23-27, 2026; Madrid, Spain. Abstract LBA11.
Related to this article








